Baird Financial Group
CGTX icon

Baird Financial Group’s Cognition Therapeutics CGTX Stock Holding History

Baird Financial Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,393
Closed -$37.2K – 1758
2024
Q2 		$37.2K Hold
22,393
– – ﹤0.01% 1739
2024
Q1 		$40.8K Hold
22,393
– – ﹤0.01% 1737
2023
Q4 		$41.4K Hold
22,393
– – ﹤0.01% 1692
2023
Q3 		$32.2K Hold
22,393
– – ﹤0.01% 1691
2023
Q2 		$41K Hold
22,393
– – ﹤0.01% 1672
2023
Q1 		$44.3K Buy
22,393
+2,300
+11% +$4.38K ﹤0.01% 1670
2022
Q4 		$42K Sell
20,093
-20,693
-51% -$41.8K ﹤0.01% 1668
2022
Q3 		$77K Buy
40,786
+20,393
+100% +$42.5K ﹤0.01% 1679
2022
Q2 		$43K Hold
20,393
– – ﹤0.01% 1756
2022
Q1 		$56K Buy
+20,393
New +$78.6K ﹤0.01% 1785

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Baird Financial Group's CGTX Position: Q3 2024 in Review

Baird Financial Group sold out of Cognition Therapeutics (CGTX) in Q3 2024, closing a stake of 22,393 shares — an estimated $37.2K sold.

Baird Financial Group first reported a position in CGTX in Q1 2022 and held it in 10 quarters. The position peaked at $77K in Q3 2022. 40 funds tracked by Wall St. Rank hold CGTX as of Q3 2024.

  • Baird Financial Group reported no remaining Cognition Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baird Financial Group sold 22,393 Cognition Therapeutics shares in Q3 2024, an estimated $37.2K.
  • Baird Financial Group first reported a position in Cognition Therapeutics in Q1 2022 and held it in 10 quarters.
  • Baird Financial Group's Cognition Therapeutics position peaked at $77K in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2024.

Based on Baird Financial Group's 13F filing for Q3 2024, filed 14 Nov 2024.